Literature DB >> 15047819

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope.

Zhi-yong Yang1, Bimal K Chakrabarti, Ling Xu, Brent Welcher, Wing-pui Kong, Kwanyee Leung, Amos Panet, John R Mascola, Gary J Nabel.   

Abstract

Although the B clade of human immunodeficiency virus type 1 (HIV-1) envelopes (Env) includes five highly variable regions, each of these domains contains a subset of sequences that remain conserved. The V3 loop has been much studied for its ability to elicit neutralizing antibodies, which are often restricted to a limited number of closely related strains, likely because a large number of antigenic structures are generated from the diverse amino acid sequences in this region. Despite these strain-specific determinants, subregions of V3 are highly conserved, and the effects of different portions of the V3 loop on Env tropism and immunogenicity have not been well delineated. For this report, selective deletions in V3 were introduced by shortening of the stem of the V3 loop. These mutations were explored in combination with deletions of selected V regions. Progressive shortening of the stem of V3 abolished the immunogenicity as well as the functional activity of HIV Env; however, two small deletions on both arms of the V3 stem altered the tropism of the dualtropic 89.6P viral strain so that it infected only CXCR4(+) cells. When this smaller deletion was combined with removal of the V1 and V2 loops and used as an immunogen in guinea pigs, the antisera were able to neutralize multiple independent clade B isolates with a higher potency. These findings suggest that highly conserved subregions within V3 may be relevant targets for eliciting neutralizing antibody responses, affecting HIV tropism, and increasing the immunogenicity of AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047819      PMCID: PMC374252          DOI: 10.1128/jvi.78.8.4029-4036.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages).

Authors:  D R Briggs; D L Tuttle; J W Sleasman; M M Goodenow
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

Review 2.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Authors:  P W Parren; J P Moore; D R Burton; Q J Sattentau
Journal:  AIDS       Date:  1999       Impact factor: 4.177

3.  Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

Authors:  R Bures; A Gaitan; T Zhu; C Graziosi; K M McGrath; J Tartaglia; P Caudrelier; R El Habib; M Klein; A Lazzarin; D M Stablein; M Deers; L Corey; M L Greenberg; D H Schwartz; D C Montefiori
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

4.  Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5.

Authors:  M Purtscher; A Trkola; A Grassauer; P M Schulz; A Klima; S Döpper; G Gruber; A Buchacher; T Muster; H Katinger
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

5.  V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.

Authors:  C P Krachmarov; S C Kayman; W J Honnen; O Trochev; A Pinter
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

6.  Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys.

Authors:  G B Karlsson; M Halloran; J Li; I W Park; R Gomila; K A Reimann; M K Axthelm; S A Iliff; N L Letvin; J Sodroski
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction.

Authors:  Christophe Guillon; Martin Schutten; Patrick H M Boers; Rob A Gruters; Albert D M E Osterhaus
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.

Authors:  John R Mascola; Mark K Louder; Christine Winter; Ranjani Prabhakara; Stephen C De Rosa; Daniel C Douek; Brenna J Hill; Dana Gabuzda; Mario Roederer
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

Authors:  M K Gorny; T C VanCott; C Hioe; Z R Israel; N L Michael; A J Conley; C Williams; J A Kessler; P Chigurupati; S Burda; S Zolla-Pazner
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

10.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

View more
  41 in total

1.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

2.  Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates.

Authors:  Lukas Flatz; Cheng Cheng; Lingshu Wang; Kathryn E Foulds; Sung-Youl Ko; Wing-Pui Kong; Rahul Roychoudhuri; Wei Shi; Saran Bao; John-Paul Todd; Mohammed Asmal; Ling Shen; Mitzi Donaldson; Stephen D Schmidt; Jason G D Gall; Daniel D Pinschewer; Norman L Letvin; Srinivas Rao; John R Mascola; Mario Roederer; Gary J Nabel
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.

Authors:  Sampa Santra; Michael S Seaman; Ling Xu; Dan H Barouch; Carol I Lord; Michelle A Lifton; Darci A Gorgone; Kristin R Beaudry; Krisha Svehla; Brent Welcher; Bimal K Chakrabarti; Yue Huang; Zhi-Yong Yang; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Comparing antigenicity and immunogenicity of engineered gp120.

Authors:  Suganya Selvarajah; Bridget Puffer; Ralph Pantophlet; Mansun Law; Robert W Doms; Dennis R Burton
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.

Authors:  Lan Wu; Wing-Pui Kong; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Authors:  Franck Lemiale; Hedi Haddada; Gary J Nabel; Douglas E Brough; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

7.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

8.  Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Authors:  John R Mascola; Anna Sambor; Kristin Beaudry; Sampa Santra; Brent Welcher; Mark K Louder; Thomas C Vancott; Yue Huang; Bimal K Chakrabarti; Wing-Pui Kong; Zhi-Yong Yang; Ling Xu; David C Montefiori; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

10.  Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity.

Authors:  Chantelle L Hood; Jonathan Abraham; Jeffrey C Boyington; Kwanyee Leung; Peter D Kwong; Gary J Nabel
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.